Genomics

Dataset Information

0

Highly Potent and Selective Interleukin-1 Receptor-Associated Kinase 4 Inhibitors for the Treatment of Lymphoid Malignancies


ABSTRACT: Pathologic activation of the Toll-like receptor (TLR) pathway underlies various human disorders such as autoimmune diseases, chronic inflammatory diseases and lymphoid malignancies. Current therapy of these diseases relies on immunosuppressive or chemotherapeutic agents, but more effective therapeutics tailored to disease-causing mechanisms are needed. Pivotal to TLR signaling is the IL-1 receptor-associated kinase 4 (IRAK4), which is recruited to TLRs by the adaptor protein MyD88. Recruitment of IRAK kinases to MyD88, triggers the formation of a signaling competent myddosome complex, which underlies the pathogenesis of many immuno-inflammatory disorders, suggesting that IRAK4 inhibitors might be useful in the treatment of these diseases. Gain-of-function MYD88 mutations activate IRAK4 in several mature B cell malignancies, including activated B-cell-like diffuse large B cell lymphoma (ABC DLBCL). Development of selective IRAK4 inhibitors has been confounded by the challenging structure of the IRAK4 catalytic domain. Using structure-based drug design methodologies, we identified potent and selective IRAK4 inhibitors. These small molecules suppress LPS-induced TNFalpha production in vitro and in vivo, and are efficacious in mouse models of collagen-induced arthritis and MyD88-dependent inflammatory gout. Human ABC DLBCL cell lines that harbor the activating, oncogenic MyD88 L265P mutation are killed by IRAK4 inhibitors, both in vitro and in mouse xenograft models. IRAK4 inhibitors synergize with the BTK inhibitor ibrutinib, with the Syk inhibitor PRT062607, and with the Bcl-2 inhibitor ABT-199 in killing ABC DLBCL cells, suggesting new therapeutic strategies for this refractory cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE63029 | GEO | 2015/11/01

SECONDARY ACCESSION(S): PRJNA266478

REPOSITORIES: GEO

Similar Datasets

2015-11-01 | E-GEOD-63029 | biostudies-arrayexpress
2014-05-21 | E-GEOD-47147 | biostudies-arrayexpress
2014-05-21 | GSE47147 | GEO
2010-12-30 | E-GEOD-22900 | biostudies-arrayexpress
2018-05-01 | GSE99276 | GEO
2017-10-12 | GSE86234 | GEO
2010-12-30 | GSE22900 | GEO
2009-06-01 | E-GEOD-11902 | biostudies-arrayexpress
2017-02-08 | GSE86265 | GEO
2017-02-08 | GSE86264 | GEO